Mesoblast Shares Rise 9.5% as Phase 3 Patient Treatment Completes for Chronic Low Back Pain
MESO Mesoblast Ltd ADR
$17.02 +9.14%
View chart & analysis → 
- 1Mesoblast (MESO) shares climbed 9.5% after the company completed patient treatment in the Phase 3 trial of its chronic low back pain therapy rexlemestrocel-L
- 2In MSB-DR004, 350 patients were randomized to receive a single intradiscal injection or a sham injection, expanded from the originally planned 300
- 3The primary endpoint is confirmation of sustained pain reduction at 12 months, with topline results expected in mid-2027 after final patient follow-up
This 3-line summary is compiled from the report below.
InvestorsHub +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다